Claims about the benefits of pomegranate made in unpaid-for media appearances should not qualify as “advertising” under the FTC Act, argues POM Wonderful. Among the claims FTC is pursuing, POM owner Lynda Resnick told Newsweek that pomegranate juice is “40 percent as effective as Viagra.”
[POM Wonderful LLC] maintains its executives’ media appearances were not commercial speech under Federal Trade Commission statute, a concept that, if upheld, could affect FTC’s ability to pursue claims made outside traditional paid-for advertisements.
The company filed an answering brief with FTC July 18, rejecting the agency’s attempt to frame TV and...
The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.
Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”
Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
